CN102579376B - 一种非甾体抗炎药口腔崩解片及其制备方法 - Google Patents
一种非甾体抗炎药口腔崩解片及其制备方法 Download PDFInfo
- Publication number
- CN102579376B CN102579376B CN201110009441.4A CN201110009441A CN102579376B CN 102579376 B CN102579376 B CN 102579376B CN 201110009441 A CN201110009441 A CN 201110009441A CN 102579376 B CN102579376 B CN 102579376B
- Authority
- CN
- China
- Prior art keywords
- meloxicam
- oral cavity
- mixture
- freeze
- nsaid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 112
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 title abstract description 130
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 title abstract description 129
- 210000000214 mouth Anatomy 0.000 title abstract description 105
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 66
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 57
- 239000003814 drug Substances 0.000 claims abstract description 31
- 238000000034 method Methods 0.000 claims abstract description 25
- 238000004108 freeze drying Methods 0.000 claims abstract description 21
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 142
- 239000000243 solution Substances 0.000 claims description 99
- 239000000203 mixture Substances 0.000 claims description 96
- ZRVUJXDFFKFLMG-UHFFFAOYSA-N Meloxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 claims description 81
- 229960001929 meloxicam Drugs 0.000 claims description 81
- 239000004373 Pullulan Substances 0.000 claims description 75
- 229920001218 Pullulan Polymers 0.000 claims description 75
- 235000019423 pullulan Nutrition 0.000 claims description 75
- 239000004471 Glycine Substances 0.000 claims description 71
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 70
- 229930195725 Mannitol Natural products 0.000 claims description 70
- 239000000594 mannitol Substances 0.000 claims description 70
- 235000010355 mannitol Nutrition 0.000 claims description 70
- 229920001285 xanthan gum Polymers 0.000 claims description 69
- 235000010493 xanthan gum Nutrition 0.000 claims description 69
- 239000000230 xanthan gum Substances 0.000 claims description 69
- 229940082509 xanthan gum Drugs 0.000 claims description 69
- LUEWUZLMQUOBSB-FSKGGBMCSA-N (2s,3s,4s,5s,6r)-2-[(2r,3s,4r,5r,6s)-6-[(2r,3s,4r,5s,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5s,6r)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@@H](OC3[C@H](O[C@@H](O)[C@@H](O)[C@H]3O)CO)[C@@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O LUEWUZLMQUOBSB-FSKGGBMCSA-N 0.000 claims description 60
- 235000001206 Amorphophallus rivieri Nutrition 0.000 claims description 60
- 244000247812 Amorphophallus rivieri Species 0.000 claims description 60
- 229920002581 Glucomannan Polymers 0.000 claims description 60
- 229920002752 Konjac Polymers 0.000 claims description 60
- 229940046240 glucomannan Drugs 0.000 claims description 60
- 239000000252 konjac Substances 0.000 claims description 60
- 235000010485 konjac Nutrition 0.000 claims description 60
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 55
- 235000010413 sodium alginate Nutrition 0.000 claims description 55
- 239000000661 sodium alginate Substances 0.000 claims description 55
- 229940005550 sodium alginate Drugs 0.000 claims description 55
- 239000008213 purified water Substances 0.000 claims description 47
- 238000002156 mixing Methods 0.000 claims description 39
- 125000003118 aryl group Chemical group 0.000 claims description 34
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 claims description 30
- 239000007968 orange flavor Substances 0.000 claims description 30
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 claims description 25
- 235000010358 acesulfame potassium Nutrition 0.000 claims description 25
- 229960004998 acesulfame potassium Drugs 0.000 claims description 25
- 239000000619 acesulfame-K Substances 0.000 claims description 25
- 239000006191 orally-disintegrating tablet Substances 0.000 claims description 18
- 108010011485 Aspartame Proteins 0.000 claims description 16
- 239000004376 Sucralose Substances 0.000 claims description 16
- 239000000605 aspartame Substances 0.000 claims description 16
- 235000010357 aspartame Nutrition 0.000 claims description 16
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 claims description 16
- 229960003438 aspartame Drugs 0.000 claims description 16
- 235000019408 sucralose Nutrition 0.000 claims description 16
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 claims description 16
- 235000006679 Mentha X verticillata Nutrition 0.000 claims description 15
- 235000002899 Mentha suaveolens Nutrition 0.000 claims description 15
- 235000001636 Mentha x rotundifolia Nutrition 0.000 claims description 15
- 229930006000 Sucrose Natural products 0.000 claims description 14
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 14
- 239000005720 sucrose Substances 0.000 claims description 14
- 235000007119 Ananas comosus Nutrition 0.000 claims description 13
- 239000007788 liquid Substances 0.000 claims description 13
- 239000011159 matrix material Substances 0.000 claims description 12
- 235000016623 Fragaria vesca Nutrition 0.000 claims description 9
- 235000011363 Fragaria x ananassa Nutrition 0.000 claims description 9
- 238000006243 chemical reaction Methods 0.000 claims description 9
- 239000013078 crystal Substances 0.000 claims description 6
- 230000012447 hatching Effects 0.000 claims description 6
- 238000001746 injection moulding Methods 0.000 claims description 4
- 206010000087 Abdominal pain upper Diseases 0.000 claims 5
- 230000036528 appetite Effects 0.000 claims 5
- 235000019789 appetite Nutrition 0.000 claims 5
- 206010003246 arthritis Diseases 0.000 claims 5
- 201000006549 dyspepsia Diseases 0.000 claims 5
- 208000024798 heartburn Diseases 0.000 claims 5
- 206010025482 malaise Diseases 0.000 claims 2
- 244000099147 Ananas comosus Species 0.000 claims 1
- 240000009088 Fragaria x ananassa Species 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 25
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract description 8
- 238000010579 first pass effect Methods 0.000 abstract description 7
- 229940079593 drug Drugs 0.000 abstract description 6
- 230000008901 benefit Effects 0.000 abstract description 5
- 208000019505 Deglutition disease Diseases 0.000 abstract description 3
- 239000000546 pharmaceutical excipient Substances 0.000 abstract description 2
- 231100000017 mucous membrane irritation Toxicity 0.000 abstract 1
- 239000003826 tablet Substances 0.000 description 98
- 238000009472 formulation Methods 0.000 description 37
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 21
- 238000003825 pressing Methods 0.000 description 13
- 241000234671 Ananas Species 0.000 description 12
- 239000002671 adjuvant Substances 0.000 description 11
- 229960001193 diclofenac sodium Drugs 0.000 description 11
- 229960000905 indomethacin Drugs 0.000 description 11
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 11
- 229960000991 ketoprofen Drugs 0.000 description 11
- 229960002202 lornoxicam Drugs 0.000 description 11
- OXROWJKCGCOJDO-JLHYYAGUSA-N lornoxicam Chemical compound O=C1C=2SC(Cl)=CC=2S(=O)(=O)N(C)\C1=C(\O)NC1=CC=CC=N1 OXROWJKCGCOJDO-JLHYYAGUSA-N 0.000 description 11
- JGMJQSFLQWGYMQ-UHFFFAOYSA-M sodium;2,6-dichloro-n-phenylaniline;acetate Chemical compound [Na+].CC([O-])=O.ClC1=CC=CC(Cl)=C1NC1=CC=CC=C1 JGMJQSFLQWGYMQ-UHFFFAOYSA-M 0.000 description 11
- 230000008569 process Effects 0.000 description 9
- 241000220223 Fragaria Species 0.000 description 8
- 239000011230 binding agent Substances 0.000 description 8
- 210000002200 mouth mucosa Anatomy 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 7
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 7
- -1 heteroauxing class Chemical compound 0.000 description 7
- 229960001855 mannitol Drugs 0.000 description 7
- 239000000375 suspending agent Substances 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- 229920002307 Dextran Polymers 0.000 description 6
- 230000002496 gastric effect Effects 0.000 description 6
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 5
- 208000002193 Pain Diseases 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 5
- 229940072056 alginate Drugs 0.000 description 5
- 235000010443 alginic acid Nutrition 0.000 description 5
- 229920000615 alginic acid Polymers 0.000 description 5
- 238000007710 freezing Methods 0.000 description 5
- 230000008014 freezing Effects 0.000 description 5
- 229960002449 glycine Drugs 0.000 description 5
- 230000035699 permeability Effects 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 4
- 102100038277 Prostaglandin G/H synthase 1 Human genes 0.000 description 4
- 108050003243 Prostaglandin G/H synthase 1 Proteins 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 238000007907 direct compression Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 4
- 201000008482 osteoarthritis Diseases 0.000 description 4
- 230000000750 progressive effect Effects 0.000 description 4
- 241000282414 Homo sapiens Species 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 210000003296 saliva Anatomy 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- 239000004386 Erythritol Substances 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- RWZYAGGXGHYGMB-UHFFFAOYSA-N anthranilic acid Chemical compound NC1=CC=CC=C1C(O)=O RWZYAGGXGHYGMB-UHFFFAOYSA-N 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 239000007919 dispersible tablet Substances 0.000 description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- 229940009714 erythritol Drugs 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000003292 glue Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 235000015110 jellies Nutrition 0.000 description 2
- 239000008274 jelly Substances 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 230000003637 steroidlike Effects 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 206010005963 Bone formation increased Diseases 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 206010013700 Drug hypersensitivity Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 108010044467 Isoenzymes Proteins 0.000 description 1
- 208000003947 Knee Osteoarthritis Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229920003091 Methocel™ Polymers 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 239000004368 Modified starch Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 1
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- PZZYQPZGQPZBDN-UHFFFAOYSA-N aluminium silicate Chemical compound O=[Al]O[Si](=O)O[Al]=O PZZYQPZGQPZBDN-UHFFFAOYSA-N 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 229910000323 aluminium silicate Inorganic materials 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 150000001448 anilines Chemical class 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000035606 childbirth Effects 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 238000010960 commercial process Methods 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 201000005311 drug allergy Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 108010017796 epoxidase Proteins 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- JEXVQSWXXUJEMA-UHFFFAOYSA-N pyrazol-3-one Chemical compound O=C1C=CN=N1 JEXVQSWXXUJEMA-UHFFFAOYSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 230000008054 signal transmission Effects 0.000 description 1
- 210000002363 skeletal muscle cell Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
Description
组别 | 明显进步 | 进步 | 改善 | 无效 | 总有效率(%) |
R1组 | 5 | 6 | 11 | 13 | 62.9 |
R2组 | 7 | 7 | 10 | 11 | 68.6 |
T1 | 16 | 9 | 6 | 4 | 88.6 |
T2 | 16 | 9 | 6 | 4 | 88.6 |
T3 | 16 | 8 | 7 | 4 | 88.6 |
T4 | 15 | 7 | 8 | 5 | 85.7 |
T5 | 14 | 8 | 7 | 6 | 82.9 |
T6 | 15 | 7 | 8 | 5 | 85.7 |
T7 | 16 | 9 | 6 | 4 | 88.6 |
T8 | 16 | 8 | 7 | 4 | 88.6 |
T9 | 15 | 8 | 7 | 5 | 85.7 |
T10 | 14 | 8 | 7 | 6 | 82.9 |
T11 | 15 | 7 | 8 | 5 | 85.7 |
T12 | 14 | 8 | 7 | 6 | 82.9 |
T13 | 14 | 7 | 8 | 6 | 82.9 |
T14 | 16 | 9 | 6 | 4 | 88.6 |
T15 | 15 | 8 | 7 | 5 | 85.7 |
T16 | 16 | 8 | 7 | 4 | 88.6 |
T17 | 16 | 9 | 6 | 4 | 88.6 |
T18 | 14 | 8 | 7 | 6 | 82.9 |
T19 | 16 | 8 | 7 | 4 | 88.6 |
T20 | 15 | 7 | 8 | 5 | 85.7 |
T21 | 16 | 9 | 6 | 4 | 88.6 |
T22 | 15 | 8 | 7 | 5 | 85.724 --> |
T23 | 14 | 7 | 8 | 6 | 82.9 |
T24 | 14 | 8 | 7 | 6 | 82.9 |
组别 | 明显进步 | 进步 | 改善 | 无效 | 总有效率(%) |
R3组 | 6 | 5 | 11 | 13 | 62.9 |
R4组 | 7 | 7 | 10 | 11 | 68.6 |
T25 | 16 | 9 | 6 | 4 | 88.6 |
T26 | 16 | 9 | 6 | 4 | 88.6 |
T27 | 16 | 8 | 7 | 4 | 88.6 |
R5组 | 5 | 6 | 11 | 13 | 62.9 |
R6组 | 6 | 8 | 10 | 11 | 68.6 |
T28 | 15 | 10 | 6 | 4 | 88.6 |
T29 | 15 | 9 | 7 | 4 | 88.6 |
T30 | 15 | 10 | 6 | 4 | 88.6 |
R7组 | 7 | 6 | 10 | 12 | 65.7 |
R8组 | 8 | 7 | 10 | 10 | 71.4 |
T31 | 17 | 9 | 5 | 4 | 88.6 |
T32 | 17 | 9 | 5 | 4 | 88.6 |
T33 | 17 | 8 | 6 | 4 | 88.6 |
R9组 | 5 | 6 | 10 | 14 | 60.0 |
R10组 | 6 | 7 | 10 | 12 | 65.7 |
T34 | 15 | 8 | 7 | 5 | 85.7 |
T35 | 15 | 7 | 8 | 5 | 85.7 |
T36 | 15 | 8 | 7 | 5 | 85.7 |
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201110009441.4A CN102579376B (zh) | 2011-01-14 | 2011-01-14 | 一种非甾体抗炎药口腔崩解片及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201110009441.4A CN102579376B (zh) | 2011-01-14 | 2011-01-14 | 一种非甾体抗炎药口腔崩解片及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102579376A CN102579376A (zh) | 2012-07-18 |
CN102579376B true CN102579376B (zh) | 2016-04-27 |
Family
ID=46468989
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201110009441.4A Active CN102579376B (zh) | 2011-01-14 | 2011-01-14 | 一种非甾体抗炎药口腔崩解片及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102579376B (zh) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102784123A (zh) * | 2012-08-23 | 2012-11-21 | 海南卫康制药(潜山)有限公司 | 双氯芬酸钠组合物冻干口腔崩解片及其制备方法 |
CN103989649A (zh) * | 2014-05-30 | 2014-08-20 | 青岛市市立医院 | 一种氯诺昔康口腔崩解片及其制备方法 |
CN104434776A (zh) * | 2014-12-05 | 2015-03-25 | 海南卫康制药(潜山)有限公司 | 一种美洛昔康组合物冻干片及其制备方法 |
CN110652500A (zh) * | 2019-11-04 | 2020-01-07 | 杭州百诚医药科技股份有限公司 | 一种氯诺昔康冻干口崩片及其制备方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1689649A (zh) * | 2004-04-30 | 2005-11-02 | 量子高科(北京)研究院有限公司 | 一种口腔速溶制剂及其生产方法 |
CN1915215A (zh) * | 2005-08-17 | 2007-02-21 | 量子高科(北京)研究院有限公司 | 一种口腔崩解制剂 |
EP2233129A1 (en) * | 2007-12-28 | 2010-09-29 | Sawai Pharmaceutical Co., Ltd. | Oral cavity disintegrating tablet and method of producing the same |
-
2011
- 2011-01-14 CN CN201110009441.4A patent/CN102579376B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1689649A (zh) * | 2004-04-30 | 2005-11-02 | 量子高科(北京)研究院有限公司 | 一种口腔速溶制剂及其生产方法 |
CN1915215A (zh) * | 2005-08-17 | 2007-02-21 | 量子高科(北京)研究院有限公司 | 一种口腔崩解制剂 |
EP2233129A1 (en) * | 2007-12-28 | 2010-09-29 | Sawai Pharmaceutical Co., Ltd. | Oral cavity disintegrating tablet and method of producing the same |
Also Published As
Publication number | Publication date |
---|---|
CN102579376A (zh) | 2012-07-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103118662B (zh) | 制备冻干速溶多相剂型的方法 | |
CN101647814A (zh) | 一种动物角的仿生酶解产物及其用途 | |
CN102579376B (zh) | 一种非甾体抗炎药口腔崩解片及其制备方法 | |
WO2013123623A1 (zh) | 一种口腔崩解片及其制备方法 | |
CN102552191B (zh) | 一种5-ht受体激动剂口腔崩解片及其制备方法 | |
CN102961508A (zh) | 一种用于治疗前列腺炎前列腺增生的中药组合物 | |
CN103301467A (zh) | 一种稳定的掩味的盐酸氨溴索复合物及其制备方法 | |
CN102525972B (zh) | 一种钙离子拮抗剂口腔崩解片及其制备方法 | |
CN102552192A (zh) | 一种镇静催眠药口腔崩解片及其制备方法 | |
CN104524247B (zh) | 一种治疗偏头痛的药物组合物及其用途 | |
CN103494792B (zh) | 一种复方间苯三酚冻干口腔崩解片及制备方法 | |
CN116392451A (zh) | 一种塞来昔布片剂及其制备方法 | |
CN102871983B (zh) | 藤黄酸结肠定位控释片及其制备方法 | |
CN106138254A (zh) | 一种牛黄解毒口含片的制备方法及其应用 | |
CN102451165A (zh) | 罗通定口腔崩解片及其制备方法 | |
CN102451169B (zh) | 氯雷他定冻干片及其制备方法 | |
CN104225196A (zh) | 一种治疗呼吸道疾病的中药泡腾片及其制备方法 | |
CN102451167A (zh) | 一种h1受体拮抗剂口腔崩解片及其制备方法 | |
CN102349883A (zh) | 对乙酰氨基酚口腔速溶膜及其制备方法 | |
CN102525971A (zh) | 一种促胃肠动力药口腔崩解片及其制备方法 | |
CN105147632A (zh) | 一种苯巴比妥口腔崩解片及其制备方法 | |
CN102451164B (zh) | 一种镇痛药口腔崩解片及其制备方法 | |
CN105147703A (zh) | 黄柏酮在制备防治溃疡性结肠炎的药物或食品中的应用 | |
CN102451170B (zh) | 盐酸格拉司琼冻干片及其制备方法 | |
CN101627971A (zh) | 纳米结晶米格列奈钙口腔崩解片及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C53 | Correction of patent for invention or patent application | ||
CB02 | Change of applicant information |
Address after: 102200 Changping District Road, Beijing, No. 8, No. 11 building Applicant after: Quantum Hi-Tech Research Institute (Beijing) Co., Ltd. Address before: 065201 Langfang Yanjiao economic and Technological Development Zone Hebei Yingbin North Road quantum hi tech (Beijing) Research Institute Co., Ltd. Applicant before: Quantum Hi-Tech Research Institute (Beijing) Co., Ltd. |
|
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20160905 Address after: 518000 Guangdong city of Shenzhen province Nanshan District high tech Park District Technology three road No. 5 in building A building 7 floor 701 unit Patentee after: SHENZHEN FONCOO PHARMACEUTICAL CO., LTD. Address before: 102200 Changping District Road, Beijing, No. 8, No. 11 building Patentee before: Quantum Hi-Tech Research Institute (Beijing) Co., Ltd. |
|
TR01 | Transfer of patent right |
Effective date of registration: 20170317 Address after: 102200 Changping District Road, Beijing, No. 8, No. 11 building Patentee after: Quantum Hi-Tech Research Institute (Beijing) Co., Ltd. Address before: 518000 Guangdong city of Shenzhen province Nanshan District high tech Park District Technology three road No. 5 in building A building 7 floor 701 unit Patentee before: SHENZHEN FONCOO PHARMACEUTICAL CO., LTD. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20191104 Address after: Room 503, Building 11, 8 Hoying Road, Industrial Base, Changping District, Beijing 102200 (Changping Demonstration Zone) Patentee after: BEIJING QUANTUM HI-TECH PHARMACEUTICAL TECHNOLOGY CO., LTD. Address before: 102200, No. 11, building 8, Ho Ying Road, Beijing, Changping District Patentee before: Quantum High Technology (Beijing) Research Institute Co., Ltd. |
|
TR01 | Transfer of patent right |